CompletedPhase 1NCT05409196

Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults

Studying Reactive arthritis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eveliqure Biotechnologies GmbH
Principal Investigator: Dénes Páll, MD, PhD
University of Debrecen
Intervention: ShigETEC live, attenuated, oral vaccine(biological)
Enrollment: 84 enrolled
Eligibility: 18-45 years · All sexes
Timeline: 2020 – 2021

Study locations (1)

Debreceni Egyetem, Klinikai Központ, Belgyógyászati Klinika, Klinikai Farmakológiai Részleg, Debrecen, Hungary

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05409196 on ClinicalTrials.gov

Other trials for Reactive arthritis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT04751396
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center

See all trials for Reactive arthritis →

← Back to all trials